Login
Companies $REPL
$21.32 -$0.09 (0.42%) After hours
Replimune Group, Inc. logo

Replimune Group, Inc.

replimune.com

What Do They Do?

Develops oncolytic immunotherapy drug candidates for cancer treatment, including therapies aimed at skin cancers and other solid tumors.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2026 annual report
Latest quarter: Q2 FY2027, the three months to Sep 30, 2026
Net income
▲ +31% (Loss)
vs −$83.1M in Q2 FY2026
  • Aug 14, 2026 Replimune prepares to launch TUDRIQEV in the United States The company said it had begun launch preparations and expected the product to be on the market within 60 days.
  • Aug 7, 2026 FDA grants accelerated approval for TUDRIQEV with nivolumab The approval covers adults with unresectable advanced cutaneous melanoma after disease progression on an anti-PD-1 antibody-based regimen.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support